Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 10/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
| ▸ | SKP1 | P63208 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | STK4 | Q13043 | 1/20 | 0.36 |
| ▸ | STK3 | Q13188 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9897094 | 0.86 | AAK1 (0.51) | AAK1BTKEGFRERBB2 | |
| SCHEMBL9943131 | 0.86 | AAK1 (0.48) | AAK1BTKEGFR | |
| SCHEMBL9899033 | 0.86 | AAK1 (0.35) | AAK1BTKJAK3EGFRERBB2 | |
| SCHEMBL9897560 | 0.86 | BTK (0.51) | AAK1BTKJAK3KCNA3 | |
| SCHEMBL13471641 | 0.85 | BTK (0.53) | AAK1BTKJAK3 | |
| SCHEMBL9898224 | 0.84 | AAK1 (0.56) | AAK1BTKEGFRERBB2 | |
| SCHEMBL9897164 | 0.84 | AAK1 (0.50) | AAK1BTKSTK4STK3LRRK2 | |
| SCHEMBL9898208 | 0.84 | AAK1 (0.48) | AAK1BTKEGFRERBB2 | |
| SCHEMBL9899608 | 0.84 | KDR (0.34) | AAK1BTKEGFRERBB2 | |
| SCHEMBL9928279 | 0.83 | LRRK2 (0.39) | AAK1LRRK2EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| EP-2511276-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | Ube Industries, Ltd. (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | AAK1 709/4885BTK 50/4885KCNH2 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.